These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 36907642

  • 1. Diagnosis and management of post-transplant lymphoproliferative disease following solid organ transplantation in children, adolescents, and young adults.
    Rubinstein J, Toner K, Gross T, Wistinghausen B.
    Best Pract Res Clin Haematol; 2023 Mar; 36(1):101446. PubMed ID: 36907642
    [Abstract] [Full Text] [Related]

  • 2. Post-transplant lymphoproliferative disease in children, adolescents, and young adults.
    Gross TG, Rubinstein JD.
    Hematol Oncol; 2023 Jun; 41 Suppl 1():48-56. PubMed ID: 37294957
    [Abstract] [Full Text] [Related]

  • 3. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice.
    Clin Transplant; 2019 Sep; 33(9):e13652. PubMed ID: 31230381
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Management of Epstein-Barr virus-induced post-transplant lymphoproliferative disease in recipients of solid organ transplantation.
    Green M.
    Am J Transplant; 2001 Jul; 1(2):103-8. PubMed ID: 12099356
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease].
    Hao QF, Sheng GY, Luan Z.
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Sep; 15(9):795-9. PubMed ID: 24034931
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Review of Epstein-Barr virus and post-transplant lymphoproliferative disorder post-solid organ transplantation.
    Lim WH, Russ GR, Coates PT.
    Nephrology (Carlton); 2006 Aug; 11(4):355-66. PubMed ID: 16889577
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Epstein-Barr virus-induced posttransplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting.
    Paya CV, Fung JJ, Nalesnik MA, Kieff E, Green M, Gores G, Habermann TM, Wiesner PH, Swinnen JL, Woodle ES, Bromberg JS.
    Transplantation; 1999 Nov 27; 68(10):1517-25. PubMed ID: 10589949
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Comparative analysis of post-transplant lymphoproliferative disorders after solid organ and hematopoietic stem cell transplantation reveals differences in the tumor microenvironment.
    Overkamp M, Granai M, Bonzheim I, Steinhilber J, Schittenhelm J, Bethge W, Quintanilla-Martinez L, Fend F, Federmann B.
    Virchows Arch; 2021 Jun 27; 478(6):1135-1148. PubMed ID: 33324999
    [Abstract] [Full Text] [Related]

  • 16. Post-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.
    Wistinghausen B, Gross TG, Bollard C.
    Pediatr Hematol Oncol; 2013 Sep 27; 30(6):520-31. PubMed ID: 23802715
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. How I treat posttransplant lymphoproliferative disorder.
    Amengual JE, Pro B.
    Blood; 2023 Oct 26; 142(17):1426-1437. PubMed ID: 37540819
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Tabelecleucel for allogeneic haematopoietic stem-cell or solid organ transplant recipients with Epstein-Barr virus-positive post-transplant lymphoproliferative disease after failure of rituximab or rituximab and chemotherapy (ALLELE): a phase 3, multicentre, open-label trial.
    Mahadeo KM, Baiocchi R, Beitinjaneh A, Chaganti S, Choquet S, Dierickx D, Dinavahi R, Duan X, Gamelin L, Ghobadi A, Guzman-Becerra N, Joshi M, Mehta A, Navarro WH, Nikiforow S, O'Reilly RJ, Reshef R, Ruiz F, Spindler T, Prockop S.
    Lancet Oncol; 2024 Mar 26; 25(3):376-387. PubMed ID: 38309282
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.